fbpx

Health Canada Approves First ‘Bionic Eye’

The Argus II is the first retinal prosthesis system of its kind to be approved by Health Canada from Second Sight Medical Products. The “bionic eye” is used for treating outer retinal degeneration and  Retinitis Pigmentosa (RP) blindness.

The system provides electrical pulses to stimulate the retina’s remaining cells, resulting in a perception of light patterns in the brain. The implant aids shape and large object recognition, as well as people and object identification, such as finding doorways, and following lines or edges.

An estimated 13,000 people in Canada and 1.2 million people worldwide have RP. Argus II is implanted in more than 100 individuals worldwide. This Canadian approval will allow service expansion into additional provinces beyond Ontario. In June 2014, the first Canadian patient received the Argus II at the Toronto Western Hospital.

For more information, click HERE.

 

Featured Posts

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read More

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read More

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read More

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read More

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more